PAM
KLDO

Panagora Asset Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Panagora Asset Management’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-259
Closed -$2K – 3012
2020
Q4 		$2K Hold
259
– – ﹤0.01% 2677
2020
Q3 		$3K Buy
+259
New +$1.79K ﹤0.01% 2565

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Panagora Asset Management's KLDO Position: Q1 2021 in Review

Panagora Asset Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q1 2021, closing a stake of 259 shares — an estimated $2K sold.

Panagora Asset Management first reported a position in KLDO in Q3 2020 and held it in 2 quarters. The position peaked at $3K in Q3 2020. 71 funds tracked by Wall St. Rank hold KLDO as of Q1 2021.

  • Panagora Asset Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Panagora Asset Management sold 259 Kaleido Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $2K.
  • Panagora Asset Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Panagora Asset Management's Kaleido Biosciences, Inc. Common Stock position peaked at $3K in Q3 2020.
  • 71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q1 2021.

Based on Panagora Asset Management's 13F filing for Q1 2021, filed 12 May 2021.